Estimation of triple prognostic factors: serum ferritin, D-dimer and HbA1c levels in post-COVID mucormycosis patients: a cross-sectional observational study

Nishant Gupta; Siddharth Nirwan; Pawan Singhal; Samta Verma; Mansi Raj; Jitendra Kumar Jangir; Kailash Singh Jat; Anjani Kumar Sharma

doi:10.18203/issn.2454-5929.ijohns20230313

Authors

Nishant Gupta Department of ENT, SMS Medical College, Jaipur, Rajasthan, India
Siddharth Nirwan Department of ENT, SMS Medical College, Jaipur, Rajasthan, India
Pawan Singhal Department of ENT, SMS Medical College, Jaipur, Rajasthan, India
Samta Verma Department of ENT, SMS Medical College, Jaipur, Rajasthan, India
Mansi Raj Department of ENT, SMS Medical College, Jaipur, Rajasthan, India
Jitendra Kumar Jangir Department of ENT, SMS Medical College, Jaipur, Rajasthan, India
Kailash Singh Jat Department of ENT, SMS Medical College, Jaipur, Rajasthan, India
Anjani Kumar Sharma Department of ENT, SMS Medical College, Jaipur, Rajasthan, India

DOI:

https://doi.org/10.18203/issn.2454-5929.ijohns20230313

Keywords:

COVID-19, Mucormycosis, Serum ferritin, D-Dimer, HbA1c

Abstract

Background: India was furiously hit by the second wave of COVID-19 that peaked during the months of April and May 2021. It led to an unprecedented number of rhino-orbital-cerebral mucormycosis cases that came as a bitter surprise. Several parameters were found to be consistently elevated in the patients like serum ferritin, D-dimer, and HbA1C.

Methods: A cross-sectional observational study was conducted at the SMS medical college that included 120 patients presenting with post-COVID mucormycosis from 1^st May to 31^st May 2021. HbA1c, D-dimer, serum ferritin levels were measured at the time of admission.

Results: Our study showed a mean range of serum ferritin of 539.6±484.9, mean D-dimer range was 636.3±303.5, both of which were higher than normal. In the present study 94.1% of the patients had diabetes mellitus. Among them 60.80% of the patients had newly detected diabetes and 33.30% were known cases of diabetes with mean HbA1c 9.7±2.3. The p value was less than 0.001 which was statistically significant.

Conclusions: Timely detection and categorization of the patients based on severity of the above parameters can not only help in executing the existing institutional resources but can also help in saving valuable lives, and preventing radical surgical procedures like orbital exenteration and maxillectomy.

Metrics

Metrics Loading ...

References

Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-53.

World Health Organization Coronavirus disease 2019 (COVID-19) dashboard. Available at: https://covid19.who.int. Accessed on 25 December 2022.

Talmi YP, Goldschmied-Reouven A, Bakon M, Barshack I, Wolf M, Horowitz Z, et al. Rhino-orbital and rhino-orbito-cerebral mucormycosis, Otolaryngol. Head Neck Surg. 2002;127(1):22-31.

Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020;95:304-07.

Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y. The Hyperferritinemic Syndrome: Macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185.

Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29:401-9.

Mignogna MD, Fortuna G, Leuci S. Mucormycosis in immunocompetent patients: a case-series of patients with maxillary sinus involvement and a critical review of the literature. Int J Infect Dis. 2011;15(8):e533-40.

Rudramurthy SM, Hoenigl M, Meis JF. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses 2021;64(9):1028-37.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054-62

Goddanti N, Reddy YM, Kumar MK. Role of COVID-19 Inflammatory Markers in Rhino-Orbito-Cerebral Mucormycosis: A Case Study in Predisposed Patients at a Designated Nodal Centre. Indian J Otolaryngol Head Neck Surg. 2022;74(2):3498-504.

Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol. 2012;50(6):611-8.

Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014;6(4):748-73.

Nayak PS, Katyal I, Kumar AD. COVID 19 Associated Mucormycosis: Preventable Risk Factors Leading to a Better Prognosis: A Case Series. Indian J Otolaryngol Head Neck Surg. 2022;74(2):3536-40.

Lenus S, Ramadevi M, Muneeswar R, Jaya B, Bhavana A. A Study to Identify the Risk Factors and their Relationship with Mucormycosis Severity in COVID Pneumonia. Eur J Clinical Med. 2022;3(1):37-40.

Mishra N, Mutya VSS, Thomas A, Rai G, Reddy B, Mohanan AA, et al. A case series of invasive mucormycosis in patients with COVID-19 infection. Intern J Otorhinolaryngol Head Neck Surg. 2021;7(5):867-70.

Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes and Metabolic Syndrome. Clin Res Rev. 2021;15(4):102146.

Kaneria MV, Baligeri K, Budhe A. Post COVID-19 mucormycosis: A case series. Asian Pac J Trop Med 2021;14:517-24.